Cite
Dapavo P, Siliquini N, Mastorino L, et al. Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study. J Dermatolog Treat. 2021;1-6doi: 10.1080/09546634.2021.1961998.
Dapavo, P., Siliquini, N., Mastorino, L., Avallone, G., Merli, M., Agostini, A., Cariti, C., Viola, R., Stroppiana, E., Verrone, A., Ortoncelli, M., Quaglino, P., & Ribero, S. (2021). Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study. The Journal of dermatological treatment, 1-6. https://doi.org/10.1080/09546634.2021.1961998
Dapavo, Paolo, et al. "Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study." The Journal of dermatological treatment vol. (2021): 1-6. doi: https://doi.org/10.1080/09546634.2021.1961998
Dapavo P, Siliquini N, Mastorino L, Avallone G, Merli M, Agostini A, Cariti C, Viola R, Stroppiana E, Verrone A, Ortoncelli M, Quaglino P, Ribero S. Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study. J Dermatolog Treat. 2021 Aug 13;1-6. doi: 10.1080/09546634.2021.1961998. Epub 2021 Aug 13. PMID: 34315331.
Copy
Download .nbib